004720 — PharmGen Science Balance Sheet
0.000.00%
Last trade - 00:00
- KR₩96bn
- KR₩97bn
- KR₩167bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 15,394 | 30,448 | 34,187 | 19,886 | 37,437 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 19,772 | 24,020 | 20,166 | 28,638 | 36,414 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 50,615 | 74,901 | 77,379 | 70,541 | 95,327 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 15,595 | 17,214 | 34,902 | 42,444 | 41,273 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 100,035 | 135,544 | 220,324 | 317,391 | 335,917 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 30,340 | 37,688 | 71,122 | 68,185 | 63,172 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 43,931 | 52,018 | 93,384 | 110,267 | 107,696 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 56,104 | 83,526 | 126,940 | 207,125 | 228,221 |
Total Liabilities & Shareholders' Equity | 100,035 | 135,544 | 220,324 | 317,391 | 335,917 |
Total Common Shares Outstanding |